KRAS基因突变与大肠癌临床病理特征及预后的关系

Association of KRAS gene mutation and clinicopathological features and prognosis of colorectal carcinoma

目的探讨KRAS基因突变与大肠癌临床病理特征及预后的关系。方法应用实时荧光定量PCR法检测90例大肠癌患者KRAS基因突变情况,分析大肠癌KRAS基因突变与临床病理特征及预后的意义。结果 90例患者大肠癌标本中,33例患者检测出KRAS基因突变,突变率为36.7%。有淋巴结转移及有远处转移患者KRAS基因突变率分别高于无淋巴结转移及无远处转移患者(P<0.01)。不同性别、年龄、肿块大小、浸润深度、病理组织学类型患者的KRAS基因突变率差异均无统计学意义(P>0.05)。KRAS基因突变型患者3年生存率低于KRAS基因野生型患者(69.7% vs.96.5%)(P<0.01)。结论检测KRAS基因突变对大肠癌的治疗及预后评估具有重要的意义。

Objective To analyze the association of KRAS gene mutation and clinicopathological features and prognosis in the patients with colorectal cancer. Methods The mutation of KRAS gene in 90 patients with eolorectal cancer was detected by real-time quantitative PCR. The significances of KRAS gene mutation and clinicopathological features and prognosis were analyzed. Results Of 90 cases with colorectal cancer, 33 cases （36.7%） were tested for KRAS mutations. The mutation rate of KRAS gene in the patients with lymph node metastasis and distant metastasis was higher than that without lymph node metastasis and distant metastasis（P〈0. 01）. There were no significant differences in the KRAS gene mutation rates in the patients of different sex, age, tumor size,depth of invasion and histopathological type（ P〉0. 05）. The 3-year survival rate of patients with KRAS gene mutant type was lower than that of those with KRAS gene wild type （69.7% vs. 96.5%）（P〈0. 01）. Conclusion The detection of KRAS gene mutation has an important significance in the treatment and evaluation of prognosis in the patients with colorectal cancer.